Artelo Biosciences (NASDAQ:ARTL) Issues Earnings Results, Misses Expectations By $0.17 EPS

Artelo Biosciences (NASDAQ:ARTL) announced its quarterly earnings data on Wednesday. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.17), FiscalAI reports.

Artelo Biosciences Stock Performance

ARTL traded down $0.01 on Wednesday, hitting $0.73. 84,405 shares of the company were exchanged, compared to its average volume of 1,856,826. Artelo Biosciences has a fifty-two week low of $0.71 and a fifty-two week high of $31.65. The firm has a market capitalization of $1.71 million, a P/E ratio of -0.02 and a beta of -0.07. The business’s fifty day moving average is $1.09 and its 200 day moving average is $3.11.

Analyst Ratings Changes

Several research firms have recently commented on ARTL. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a report on Wednesday, June 24th. Wall Street Zen raised Artelo Biosciences from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $54.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.